Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) insider Kristen Yen sold 2,218 shares of Soleno Therapeutics stock in a transaction on Monday, April 1st. The stock was sold at an average price of $41.34, for a total transaction of $91,692.12. Following the completion of the transaction, the insider now owns 23,422 shares in the company, valued at approximately $968,265.48. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Kristen Yen also recently made the following trade(s):
- On Thursday, January 25th, Kristen Yen sold 397 shares of Soleno Therapeutics stock. The stock was sold at an average price of $48.30, for a total transaction of $19,175.10.
Soleno Therapeutics Stock Performance
SLNO stock opened at $41.76 on Thursday. The company's 50 day moving average price is $45.92 and its 200 day moving average price is $35.28. Soleno Therapeutics, Inc. has a fifty-two week low of $2.20 and a fifty-two week high of $53.82. The firm has a market capitalization of $1.36 billion, a price-to-earnings ratio of -14.06 and a beta of -1.56.
Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last issued its quarterly earnings results on Wednesday, March 6th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.02). Equities analysts forecast that Soleno Therapeutics, Inc. will post -1.23 EPS for the current fiscal year.
Institutional Trading of Soleno Therapeutics
Charles Payne’s Gift to Stock Investors
From Unstoppable Prosperity | Ad
Right now, millions of good honest folks are feeling the squeeze.
Last year's terrible market did a number on their accounts.
Stock values plunged.
Retirement accounts lost too.
Watch Insider's Advantage Event Tuesday at 4:00 PM ET
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SLNO. Vivo Capital LLC boosted its holdings in Soleno Therapeutics by 162.8% in the 4th quarter. Vivo Capital LLC now owns 8,418,093 shares of the company's stock worth $338,828,000 after acquiring an additional 5,215,000 shares during the period. Nantahala Capital Management LLC grew its stake in shares of Soleno Therapeutics by 627.9% in the fourth quarter. Nantahala Capital Management LLC now owns 2,856,351 shares of the company's stock worth $114,968,000 after purchasing an additional 2,463,947 shares in the last quarter. Perceptive Advisors LLC bought a new position in shares of Soleno Therapeutics in the second quarter worth $9,471,000. Worth Venture Partners LLC bought a new position in shares of Soleno Therapeutics in the first quarter worth $377,000. Finally, Adage Capital Partners GP L.L.C. bought a new position in Soleno Therapeutics during the third quarter valued at about $39,160,000. Hedge funds and other institutional investors own 97.42% of the company's stock.
Analysts Set New Price Targets
SLNO has been the topic of several recent analyst reports. Stifel Nicolaus initiated coverage on shares of Soleno Therapeutics in a research note on Tuesday, January 23rd. They issued a "buy" rating and a $63.00 price target on the stock. Piper Sandler began coverage on shares of Soleno Therapeutics in a research note on Monday, February 5th. They issued an "overweight" rating and a $93.00 target price for the company. Finally, Oppenheimer lifted their price objective on shares of Soleno Therapeutics from $44.00 to $47.00 and gave the company an "outperform" rating in a research note on Tuesday, January 2nd. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $55.60.
Read Our Latest Analysis on SLNO
Soleno Therapeutics Company Profile
(
Get Free Report)
Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
